Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 10/20 | 0.39 |
| ▸ | EDNRA | P25101 | 4/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4922812 | 0.89 | THRB (0.41) | ACACBMEN1KMT2A | |
| SCHEMBL4701387 | 0.83 | EPHX2 (0.36) | ACACBEDNRAHRH3KCNH2 | |
| SCHEMBL3577481 | 0.83 | EPHX2 (0.36) | ACACBEDNRAHRH3KCNH2MEN1 | |
| SCHEMBL4912750 | 0.82 | EPHX2 (0.41) | HRH3KCNH2FAAH | |
| SCHEMBL4922019 | 0.79 | EPHX2 (0.36) | HRH3KCNH2FAAH | |
| SCHEMBL4922516 | 0.78 | EPHX2 (0.44) | FAAH | |
| SCHEMBL4922648 | 0.78 | MEN1 (0.37) | ACACBEDNRAMEN1HTTKMT2A | |
| SCHEMBL3583067 | 0.76 | KMO (0.38) | EDNRAHRH3KCNH2 | |
| SCHEMBL3571629 | 0.73 | EGLN1 (0.40) | ACACBKCNH2 | |
| SCHEMBL4914773 | 0.73 | PDE4A (0.36) | ACACBEDNRAHRH3KCNH2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, ARG1 | ACACB 3817/4885EDNRA 39/4885GRM4 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.